Statement of changes in beneficial ownership of securities



STYLE="font: 10pt Times New Roman, Times, Serif">



Exhibit 24.1








POWER OF ATTORNEY





Know all by these presents,
that the undersigned hereby constitutes and appoints each of Jerome B. Durso, Jared Freedberg, Rocco Venez ia, and Mary J. Grendell of
Intercept Pharmaceuticals, Inc. (the “Company”), signing singly, with full power of substitution, as the undersigned’s
true and lawful attorney-in-fact to:












1.

execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer, director and/or more than 10% stockholder
of the Company, Forms 3, 4 and 5 (including any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of
1934 and the rules thereunder, and any other forms or reports (including any amendments thereto) the undersigned may be required to file
in connection with the undersigned’s ownership, acquisition or disposition of securities of the Company;











2.

do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any
such Form 3, 4 or 5 or other form or report (including any amendments thereto), and timely file such form or report (including any amendments
thereto) with the U.S. Securities and Exchange Commission and any stock exchange, self-regulatory or similar authority; and











3.

take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may
be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by
such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms
and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.




The undersigned hereby grants to each such attorney-in-fact
full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise
of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally
present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s
substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned,
are not assuming, nor is the Company assuming, (i) any of the undersigned’s responsibilities to comply with Section 16 of the Securities
Exchange Act of 1934, as amended, or any liability for the undersigned’s failure to comply therewith or (ii) any obligation or liability
that the undersigned incurs for profit disgorgement under Section 16(b) of the Securities Exchange Act of 1934, as amended.





The undersigned agrees that each such attorney-in-fact
may rely entirely on information furnished orally or in writing by the undersigned to such attorney-in-fact. The undersigned also agrees
to indemnify and hold harmless the Company and each such attorney-in-fact against any losses, claims, damages or liabilities (or actions
in these respects) that arise out of or are based upon any untrue statements or omission of necessary facts in the information provided
by the undersigned to such attorney-in-fact for purposes of executing, acknowledging, delivering or filing Forms 3, 4 or 5 or other forms
or reports (including any amendments thereto) and agrees to reimburse the Company and such attorney-in-fact for any legal or other expenses
reasonably incurred in connection with investigating or defending against any such loss, claim, damage, liability or action.





IN WITNESS WHEREOF, the undersigned has caused
this Power of Attorney to be executed as of April 29, 2021.

















/s/ Srinivas Akkaraju


Name: Srinivas Akkaraju













The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Intercept Pharmaceuticals makes a similar move, sign up!

Other recent filings from the company include the following:

Intercept Pharmaceuticals's Chief Qual. Officer & SVP Ops. just disposed of 2,455 shares - Jan. 13, 2022
Departure of Directors or Certain - Jan. 10, 2022
Statement of changes in beneficial ownership of securities - Jan. 4, 2022
SVP of Intercept Pharmaceuticals just disposed of 2,455 shares - Jan. 4, 2022
Intercept Pharmaceuticals's Chief Human Resources Officer just disposed of 1,712 shares - Jan. 4, 2022

Auto Refresh

Feedback